Moderna's 177% Single-Day Surge: Wall Street Splits Over Whether One Trial Justifies a New Era

Moderna's stock surges 367% YTD after landmark Phase-3 mRNA cancer vaccine success with Merck, but analyst targets diverge widely.

The numbers are almost too large to process. A 177 percent single-day gain on August 19, followed by another 8.6 percent advance on Friday. A 367 percent climb since the start of the year. A 52-week range that stretches from 19.36 euros to 149.62 euros. And at the center of it all: one Phase-3 trial readout for a personalized mRNA cancer vaccine that has fundamentally rewired how investors think about Moderna.

The study in question, INTerpath-001, tested intismeran autogene (V940) alongside Merck's checkpoint inhibitor Keytruda in patients with resected stage IIB-IV melanoma. The data hit its primary endpoint of recurrence-free survival, plus a key secondary endpoint around metastasis-free survival. Reuters called it the first positive late-stage result ever for an mRNA cancer vaccine — a historic first that explains why the stock has been in a state of exception ever since.

A Rally With Two Parents

What's easy to miss in the frenzy is that this success isn't Moderna's alone. Merck, which co-developed the combination therapy, also saw its shares move on the news. More than 1,100 patients were enrolled in the trial, underscoring how much of the value driver here is a partnership — not a standalone Moderna asset. Anyone buying the stock is effectively betting on a joint program whose overall survival data and full results are still pending.

That hasn't stopped the analyst community from redrawing its maps. Bank of America upgraded the stock on August 20 from "Underperform" to "Neutral," lifting its price target from 40 to 170 dollars and describing the data as a "watershed moment" for the mRNA platform. Jefferies followed a day later with its own 170-dollar target, citing a potential global peak sales figure of roughly 54 billion dollars for the personalized oncology platform.

The bull case rests on platform logic: if a tailored mRNA vaccine can cut recurrence risk in melanoma when paired with an established checkpoint inhibitor, the same approach could theoretically extend to other tumor types. Moderna's president, Stephen Hoge, has flagged readouts in other cancers over the next one to two years. Mid-stage studies are already running in bladder and kidney cancer, with earlier-stage work in pancreatic and stomach cancer. The company has also pointed to thousands of melanoma patients potentially benefiting within the first years after approval. And with the FDA nod for mFLUSIVA in early August, Moderna has shown its technology can be commercialized beyond Covid-19.

The Skeptics' Arithmetic

But the counter-position carries weight. Goldman Sachs kept its "Neutral" rating on August 20 with a price target of just 120 dollars. Morgan Stanley went further, holding at "Equal-weight" with an 89-dollar target — a figure that sits well below where the stock now trades. The gap between the optimists and the skeptics is not a matter of degrees; it's a chasm.

Part of the concern is mechanical. The August 19 spike was amplified by a short squeeze involving roughly twelve percent of the free float — a dynamic that can reverse as quickly as it appeared. The technical picture reinforces the caution: the RSI sits at 71.3, signaling overbought conditions, while annualized volatility of 516 percent suggests a market moving at a speed that fundamental news flow alone can't explain.

There's also the operational reality. Moderna remains a loss-making enterprise, posting a net loss of 782 million dollars in the second quarter of 2026, albeit slightly better than analysts had expected. And CEO Stéphane Bancel sold shares worth around 28.7 million dollars in early August under a Rule 10b5-1 trading plan — a move with clear tax and options-related rationale, but one that shows insider selling running parallel to the euphoria.

The Manufacturing Question

Reuters has also reported that Moderna acknowledged the production of personalized vaccines at scale is expensive and complex — a very practical problem that hangs directly over the melanoma program. Personalized medicine reads beautifully in a press release but becomes a logistical nightmare on the factory floor: every dose is tailored to an individual patient. Analysts are waiting for the full dataset and longer-term survival figures before drawing broader conclusions about the commercial outlook.

The stock's recent trajectory reflects this tension between euphoria and caution. Friday's close of 123.92 euros capped a 127 percent gain over seven days and 143 percent over thirty. The stock sits 17 percent below its 52-week high of 149.62 euros, reached as recently as Tuesday of this week, and 540 percent above its November low of 19.36 euros. A range that tells the story of the year in two numbers.

What Happens in Madrid

The next concrete test is clearly scheduled: full results from INTerpath-001 will be presented at the ESMO conference in Madrid at the end of October. Until then, the stock trades on expectations rather than fully published datasets. If the subgroup analyses in Madrid confirm the robustness of the effect across different patient populations, the platform narrative gains weight. If they disappoint, the gap between the 170-dollar targets from Jefferies and Bank of America on one side and the more restrained views from Morgan Stanley and Goldman Sachs on the other could resolve to the downside.

The current market capitalization stands at roughly 45.54 billion euros. Whether that valuation holds depends on whether this is the beginning of a new era for mRNA oncology or the euphoric spike of a single good study. The honest answer is that both can be true simultaneously. The science has reached a milestone. Whether it becomes a viable business with broad margins depends on questions that only the coming trials and the realities of manufacturing will answer.